18
total announcements
SUPRIYA.NS · 15 min delayed
Supriya Lifescience Limited
Supriya Lifescience Limited has informed the Exchange about Copy of Newspaper Publication regarding the 18th Annual General Meeting (AGM) of the Company to be held on September 24, 2026, through Video Conferencing (VC) / Other Audio Visual Means (OAVM).
Supriya Lifescience Limited
Supriya Lifescience Limited has announced the record date for the purpose of dividend as 04-Sep-2026. The company has recommended a final dividend of Re. 1.00/- per equity share of Rs. 2/- each for the FY 2025-26, subject to approval of members at the Annual General Meeting scheduled to be held on Thursday, September 24, 2026.
Supriya Lifescience Limited
Supriya Lifescience Limited has submitted the Exchange a copy Scrutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results. The company has passed the resolution for the re-appointment of Mr. Balasaheb Sawant as Whole Time Director and Key Managerial Personnel of the Company for a term of three (3) consecutive years from May 26, 2026, to May 25, 2029.
Supriya Lifescience Limited
Supriya Lifescience Limited has informed the Exchange about the transcript of the earnings call for the quarter ended June 30, 2026, where the company discussed its Q1 FY '27 results, including revenue growth, EBITDA margins, and new product launches.
Supriya Lifescience Limited
Supriya Lifescience Limited has made available the audio recording of its earnings call held on August 14, 2026, discussing its operational and financial performance for the quarter ended June 30, 2026, on its website.
Supriya Lifescience Limited
Supriya Lifescience Limited has published its unaudited financial results for the quarter ended June 30, 2026, in accordance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results show a net profit of ₹1,184 for the quarter, with a basic earnings per share of ₹0.01.
Supriya Lifescience Limited
Supriya Lifescience Ltd. has reported a 31% YoY revenue growth in Q1 FY27, with revenues standing at Rs 189.75 crore compared to Rs 145.07 crore in Q1 FY26. The company's EBITDA margin stood at 25.0%, with a PAT of Rs 24.04 crore and a PAT margin of 12.7%.
Supriya Lifescience Limited
Supriya Lifescience Limited has informed the Exchange regarding 'Unaudited Financial Results for Quarter ended June 30, 2026'. The company has approved unaudited financial results for the quarter ended June 30, 2026, along with the Limited Review Report of the Statutory Auditors.
Supriya Lifescience Limited
Supriya Lifescience Limited has informed the Exchange about Investor Presentation with respect to the Unaudited Financial Results of the Company for the quarter ended on June 30, 2026.
Supriya Lifescience Limited
Supriya Lifescience Limited has announced the outcome of its Board Meeting held on August 13, 2026, where the Board considered and approved the unaudited financial results for the quarter ended June 30, 2026. The results are accompanied by a Limited Review Report of the Statutory Auditors.
Supriya Lifescience Limited
Supriya Lifescience Limited has informed the Exchange about a scheduled earnings call to discuss the company's unaudited financial results for the quarter ended June 30, 2026.
Supriya Lifescience Limited
Supriya Lifescience Limited has informed the Exchange about a copy of newspaper publication regarding a notice of postal ballot and e-voting information for the distribution of income option cum capital withdrawal (IOCW) under Kotak Arbitrage Fund.
Supriya Lifescience Limited
Supriya Lifescience Limited has informed the Exchange regarding Notice of Postal Ballot for re-appointment of Mr. Balasaheb Sawant as Whole Time Director and Special Key Managerial Personnel for a term of three consecutive years.
Supriya Lifescience Limited
Supriya Lifescience Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming compliance for the quarter ended June 30, 2026.
Supriya Lifescience Limited
Supriya Lifescience Limited has informed the Exchange about General Updates regarding judicial proceedings involving a Personnel of the Company. The investigation has been initiated against Mr. Sreekant Sreedharan, General Manager, Sales & Marketing officer of the Company by Special Investigation and Intelligence branch of Customs Department, subsequent to which judicial custody has been granted by CMM court till July 17, 2026. The Company remains committed to maintaining the highest standards of corporate governance and regulatory compliance.
Supriya Lifescience Limited
Supriya Lifescience Limited's promoter, Satish Waman Wagh, has submitted a disclosure under SEBI Takeover Regulations, stating that the promoter and members of the promoter group have not made any encumbrance of shares during the Financial Year ended March 31, 2026.
Supriya Lifescience Limited
Supriya Lifescience Limited announced that its Board of Directors recommended a final dividend of Re. 1.00 per equity share (50%) for the financial year 2025-26, subject to shareholder approval at the upcoming Annual General Meeting. The company also informed shareholders about the applicable tax deduction at source (TDS) provisions on this dividend payout, effective from April 1, 2020. This communication details the varying TDS rates based on shareholder category and residential status, along with the required documentation for appropriate tax deduction.
SUPRIYA
SUPRIYA has announced the closure of its trading window for all insiders and designated persons, including their immediate relatives. This closure is effective from Wednesday, July 1, 2026. The trading window will reopen 48 hours after the company declares its unaudited financial results for the quarter ending June 30, 2026. This standard regulatory measure is taken in accordance with SEBI (Prohibition of Insider Trading) Regulations, indicating the upcoming release of the company's first-quarter financial performance.